Sarepta Therapeutics annual net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Net Income Growth & History (SRPT)
Sarepta Therapeutics's net income was −$713.4M for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$713.4M | −$948.6M | — |
| 2024 | 2024-12-31 | $235.2M | $771.2M | — |
| 2023 | 2023-12-31 | −$536.0M | $167.5M | — |
| 2022 | 2022-12-31 | −$703.5M | −$284.7M | — |
| 2021 | 2021-12-31 | −$418.8M | $135.3M | — |
| 2020 | 2020-12-31 | −$554.1M | $160.9M | — |
| 2019 | 2019-12-31 | −$715.1M | −$353.2M | — |
| 2018 | 2018-12-31 | −$361.9M | −$311.2M | — |
| 2017 | 2017-12-31 | −$50.7M | $216.6M | — |
| 2016 | 2016-12-31 | −$267.3M | −$47.2M | — |
| 2015 | 2015-12-31 | −$220.0M | −$84.2M | — |
| 2014 | 2014-12-31 | −$135.8M | −$23.8M | — |
| 2013 | 2013-12-31 | −$112.0M | $9.3M | — |
| 2012 | 2012-12-31 | −$121.3M | −$119.0M | — |
| 2011 | 2011-12-31 | −$2.3M | $29.9M | — |
| 2010 | 2010-12-31 | −$32.2M | −$7.0M | — |
| 2009 | 2009-12-31 | −$25.2M | — | — |
Sarepta Therapeutics quarterly net income
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$4.9M | −$201.8M | — |
| Q1 2026 | 2026-03-31 | $331.0M | $778.5M | — |
| Q4 2025 | 2025-12-31 | −$412.2M | −$571.3M | — |
| Q3 2025 | 2025-09-30 | −$50.6M | −$84.2M | — |
| Q2 2025 | 2025-06-30 | $196.9M | $190.4M | +2947.86% |
| Q1 2025 | 2025-03-31 | −$447.5M | −$483.6M | — |
| Q4 2024 | 2024-12-31 | $159.0M | $113.4M | +248.37% |
| Q3 2024 | 2024-09-30 | $33.6M | $74.5M | — |
| Q2 2024 | 2024-06-30 | $6.5M | $30.4M | — |
| Q1 2024 | 2024-03-31 | $36.1M | $552.9M | — |
| Q4 2023 | 2023-12-31 | $45.7M | $154.9M | — |
| Q3 2023 | 2023-09-30 | −$40.9M | $216.8M | — |
| Q2 2023 | 2023-06-30 | −$23.9M | $207.5M | — |
| Q1 2023 | 2023-03-31 | −$516.8M | −$411.7M | — |
| Q4 2022 | 2022-12-31 | −$109.2M | $12.7M | — |
| Q3 2022 | 2022-09-30 | −$257.7M | −$209.6M | — |
| Q2 2022 | 2022-06-30 | −$231.5M | −$150.1M | — |
| Q1 2022 | 2022-03-31 | −$105.0M | $62.2M | — |
| Q4 2021 | 2021-12-31 | −$122.0M | $67.3M | — |
| Q3 2021 | 2021-09-30 | −$48.1M | $148.4M | — |
| Q2 2021 | 2021-06-30 | −$81.4M | $69.4M | — |
| Q1 2021 | 2021-03-31 | −$167.3M | −$149.8M | — |
| Q4 2020 | 2020-12-31 | −$189.3M | $46.4M | — |
| Q3 2020 | 2020-09-30 | −$196.5M | −$70.2M | — |
| Q2 2020 | 2020-06-30 | −$150.8M | $125.6M | — |
| Q1 2020 | 2020-03-31 | −$17.5M | $59.2M | — |
| Q4 2019 | 2019-12-31 | −$235.7M | −$94.8M | — |
| Q3 2019 | 2019-09-30 | −$126.3M | −$49.9M | — |
| Q2 2019 | 2019-06-30 | −$276.4M | −$167.1M | — |
| Q1 2019 | 2019-03-31 | −$76.6M | −$41.3M | — |
| Q4 2018 | 2018-12-31 | −$140.9M | −$116.9M | — |
| Q3 2018 | 2018-09-30 | −$76.4M | −$28.7M | — |
| Q2 2018 | 2018-06-30 | −$109.3M | −$46.2M | — |
| Q1 2018 | 2018-03-31 | −$35.4M | −$119.5M | — |
| Q4 2017 | 2017-12-31 | −$24.0M | $64.5M | — |
| Q3 2017 | 2017-09-30 | −$47.7M | $9.0M | — |
| Q2 2017 | 2017-06-30 | −$63.0M | −$745,000 | — |
| Q1 2017 | 2017-03-31 | $84.1M | $143.9M | — |
| Q4 2016 | 2016-12-31 | −$88.5M | −$23.8M | — |
| Q3 2016 | 2016-09-30 | −$56.7M | −$4.8M | — |
| Q2 2016 | 2016-06-30 | −$62.3M | −$20.4M | — |
| Q1 2016 | 2016-03-31 | −$59.8M | $1.8M | — |
| Q4 2015 | 2015-12-31 | −$64.7M | −$20.3M | — |
| Q3 2015 | 2015-09-30 | −$51.9M | −$22.7M | — |
| Q2 2015 | 2015-06-30 | −$41.9M | −$8.0M | — |
| Q1 2015 | 2015-03-31 | −$61.6M | −$33.3M | — |
| Q4 2014 | 2014-12-31 | −$44.4M | −$35.6M | — |
| Q3 2014 | 2014-09-30 | −$29.2M | $12.8M | — |
| Q2 2014 | 2014-06-30 | −$33.9M | −$14.8M | — |
| Q1 2014 | 2014-03-31 | −$28.3M | $13.8M | — |
| Q4 2013 | 2013-12-31 | −$8.8M | $53.2M | — |
| Q3 2013 | 2013-09-30 | −$42.0M | $7.5M | — |
| Q2 2013 | 2013-06-30 | −$19.1M | −$27.1M | — |
| Q1 2013 | 2013-03-31 | −$42.1M | −$24.4M | — |
| Q4 2012 | 2012-12-31 | −$62.1M | −$60.7M | — |
| Q3 2012 | 2012-09-30 | −$49.6M | −$45.5M | — |
| Q2 2012 | 2012-06-30 | $8.0M | $6.8M | +528.46% |
| Q1 2012 | 2012-03-31 | −$17.7M | −$19.5M | — |
| Q4 2011 | 2011-12-31 | −$1.4M | — | — |
| Q3 2011 | 2011-09-30 | −$4.0M | $3.3M | — |
| Q2 2011 | 2011-06-30 | $1.3M | $17.9M | — |
| Q1 2011 | 2011-03-31 | $1.8M | — | — |
| Q3 2010 | 2010-09-30 | −$7.3M | — | — |
| Q2 2010 | 2010-06-30 | −$16.7M | — | — |
Sarepta Therapeutics net income trends
Over the last five fiscal years, Sarepta Therapeutics's net income decreased from −$554.1M to −$713.4M, a change of −$159.3M. The latest reported quarter, Q2 2026, shows −$4.9M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...